BB-101 for Treatment of Diabetic Lower Leg and Foot Ulcers

• ClinicalTrials.gov Identifier: NCT03888053
• Recruitment Status: Active, not recruiting
• First Posted: March 25, 2019
• Last Update Posted: March 20, 2023
• Sponsor: Blue Blood Biotech Corp.
• Information provided by (Responsible Party): Blue Blood Biotech Corp.

Tracking Information

• First Submitted Date: February 20, 2019
• First Posted Date: March 25, 2019
• Last Update Posted Date: March 20, 2023
• Actual Study Start Date: March 28, 2018
• Actual Primary Completion Date: November 30, 2022 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: March 21, 2019)

• Incidence and severity of local reactions [ Time Frame: 6 weeks ]
  To assess the incidence of local reactions for target ulcer and surrounding area and record the severity
• Incidence and severity of adverse events [ Time Frame: 6 weeks ]
  To assess the incidence of adverse events and record the severity
• Incidence of clinical laboratory abnormalities [ Time Frame: 6 weeks ]
  To assess the incidence of clinical laboratory abnormalities
• Change from baseline in ECG [ Time Frame: 6 weeks ]
  To assess the change of baseline in ECG
• Change from baseline in blood pressure [ Time Frame: 6 weeks ]
  To assess the change of baseline in in blood pressure
• Change from baseline in heart rate [ Time Frame: 6 weeks ]
  To assess the change of baseline in heart rate
• Change from baseline in body temperature [ Time Frame: 6 weeks ]
  To assess the change of baseline in body temperature
• Presence of anti-BB-101 antibodies [ Time Frame: 6 weeks ]
  To assess the immunogenecity for BB-101

• Original Primary Outcome Measures: Same as current

Current Secondary Outcome Measures (submitted: March 21, 2019)

• Proportion of subjects with target ulcer that heals within the 4-week treatment period [ Time Frame: 4 weeks ]
  complete healing defined as re-epithelialization without drainage and dressing requirement
• To evaluate plasma concentration of BB-101 [ Time Frame: 4 weeks ]
  To evaluate plasma concentration of BB-101

• Original Secondary Outcome Measures: Same as current
• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: BB-101 for Treatment of Diabetic Lower Leg and Foot Ulcers
• Official Title: A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Topical BB-101 (rhNEGF) for the Treatment of Diabetic Lower Leg and Foot Ulcers
• Brief Summary: This is a randomized, double-blind, placebo-controlled, sequential dose escalation study in diabetic subjects with a diabetic lower leg or foot ulcer. All subjects will receive standard-of-care ulcer treatment from screening through the last study visit.

Detailed Description

This is a randomized, double-blind, placebo-controlled, sequential dose escalation study in diabetic subjects with a diabetic lower leg or foot ulcer. All subjects will receive standard-of-care ulcer treatment from screening through the last study visit.

The study will be conducted at multiple investigational sites located in Taiwan. Additional sites and countries may be added during the course of the study if required.

• Study Type: Interventional
• Study Phase: Phase 1
• Study Design: Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Double (Participant, Investigator); Primary Purpose: Treatment
• Condition: Diabetic Foot Ulcer

Intervention

Biological: BB-101

Within each cohort, 8 subjects will be randomized to receive BB-101 and 4 subjects to receive placebo.

Study Arms

• Active Comparator: BB-101 Treatment Arm
  BB-101 liquid formulation concentration of 2 µg/mL or 20 µg/mL will be applied on the target lower leg or foot ulcer once a day for 4 consecutive weeks.
  Intervention: Biological: BB-101
• Placebo Comparator: Placebo Arm
  Placebo will be applied on the target lower leg or foot ulcer once a day for 4 consecutive weeks.
  Intervention: Biological: BB-101

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Active, not recruiting
• Estimated Enrollment (submitted: August 9, 2021): 12
• Original Estimated Enrollment (submitted: March 21, 2019): 36
• Estimated Study Completion Date: December 31, 2023
• Actual Primary Completion Date: November 30, 2022 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• Male or female, 20 years of age and older.
• Type 1 or type 2 diabetes mellitus.
• Glycosylated hemoglobin (HbA1c) of ≤12%.

• A target ulcer on the lower leg or foot that meets the following criteria at screening:

  1. located below knees,
  2. Area of 0.5 - 10.0 cm^2 following sharp debridement , as measured at Visit 1 and confirmed at Visit 2,
  3. Extending through the epidermis and dermis but not involving bone, tendon or ligament,
  4. Present for ≥4 weeks prior to Visit 1 despite appropriate care, and
  5. Ulcer without clinical signs and symptoms of infection.
• Adequate arterial blood supply to the lower leg or foot under study, to be measured either by doppler ultrasonography, ankle brachial pressure index (ABPI) ≥0.70, or toe pressure >30 mmHg.
• Female subjects of childbearing potential must have a negative serum pregnancy test prior to first dose of study medication and must agree to use an effective method of contraception throughout the study. Females who are surgically sterile or have been postmenopausal for at least 1 year (12 consecutive months without menses) are exempted from these criteria. Effective methods of contraception include oral contraceptives, injectable or implantable hormonal methods, intrauterine devices, tubal ligation (if performed more than 1 year prior to screening), or double barrier contraception (e.g., diaphragm+condom).
• Subject agrees to comply with ulcer care regimen for the duration of the study.
• Subject is able to understand and sign an informed consent form and willing to comply with all study procedures.

Exclusion Criteria:

• Clinical signs and symptoms of infection of target ulcer assessed by clinical evaluation (the presence of infection is defined by ≥2 classic findings of inflammation or purulence).
• Presence of cellulitis or gangrene on the lower leg or foot under study.
• Presence of another open ulcer <2 cm away from target ulcer, on the same lower leg or foot.
• Target ulcer on the heel.
• Target ulcer caused primarily by untreated arterial insufficiency or with an etiology not related to diabetes.
• Subjects with ulcers related to an incompletely healed amputation wound.
• Acute or chronic osteomyelitis affecting the area of the target ulcer.
• Any structural deformity of the lower leg or foot under study that would prevent off- loading of the target ulcer, including acute Charcot osteoarthropathy.
• Previous use of a platelet-derived product (e.g., becaplermin) or other growth factors on the target ulcer within 4 weeks prior to Visit 1.
• Previous use of autologous graft or allogeneic graft, or dermal substitute or living skin equivalent (e.g., Dermagraft® or Apligraf®) on the target ulcer or hyperbaric oxygen therapy within 2 weeks prior to Visit 1.
• Use of any topical antimicrobials or enzymatic debridement treatment, to treat the target ulcer within 7 days prior to Visit 1.
• Treatment with systemic corticosteroids other than for inhalation, immunosuppressive agents, radiation therapy, or chemotherapeutic agent within 30 days prior to Visit 1 or likelihood to receive any of these therapies during study participation.
• History of cancer or current cancer, with the exception of adequately treated or excised non-melanoma skin cancer.
• Vasculitis, connective tissue diseases, or any medical conditions known to impair ulcer healing, other than diabetes.
• Sickle cell disease.
• Clinically significant electrocardiogram (ECG) abnormality, as determined by the Investigator.
• Any of the following laboratory results at screening: serum creatinine >2.5 mg/dL; aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2x upper limit of normal (ULN).
• Poor nutritional status (serum albumin < 2.5 g/dL).
• A history of drug or alcohol abuse that could compromise compliance or safety.
• History of human immunodeficiency virus (HIV) infection.
• Known sensitivity to any component of BB-101 or placebo.
• Participation in a clinical trial of an investigational drug or device within 30 days of study entry.
• Pregnancy, lactation, or plans to become pregnant within 6 months.
• Any social or medical condition that, in the opinion of the Investigator, would preclude provision of informed consent, make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.
• History of non-compliance with treatment or clinical visit attendance.

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 20 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: Taiwan

Administrative Information

• NCT Number: NCT03888053
• Other Study ID Numbers: BB-101-001A
• Has Data Monitoring Committee: Yes

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

• IPD Sharing Statement: Not Provided
• Current Responsible Party: Blue Blood Biotech Corp.
• Original Responsible Party: Same as current
• Current Study Sponsor: Blue Blood Biotech Corp.
• Original Study Sponsor: Same as current
• Collaborators: Not Provided

Investigators

• Principal Investigator: Shih-Chen Pan, MD; National Cheng-Kung University Hospital

• PRS Account: Blue Blood Biotech Corp.
• Verification Date: March 2023